The aim of this study is exploring rates and danger factors for genuine security occasions (SSEs) during rituximab treatment of various sclerosis (MS), neuromyelitis optica range issues (NMOSD), and related issues are restricted. Rituximab‐treated patients with MS, NMOSD, or related problems at the Rocky Mountain and New York University MS Care Centers were incorporated. The follow‐up period was characterized as the time from the underlying portion of rituximab as long as a year of last portion of rituximab or ocrelizumab (in patients who exchanged).

Clinician‐reported and lab information were reflectively gathered from electronic clinical records. Infections were the most common SAE reported in phase 2 clinical trials of rituximab for MS, but none were grade 4. One‐thousand patients were incorporated containing 907 MS, 77 NMOSD, and 16 related issues. Patients had a mean follow‐up of 31.1 months and a mean total rituximab portion of 4012 mg. Of the 169 patients who changed to ocrelizumab, the mean ocrelizumab portion was 1141 mg. Data for each center were stored on a secure server using REDcap Software. Data were de‐identified prior to being merged into a single Excel database for analysis.

Reference link-